Iovance Biotherapeutics Logo
US4622601007
A2DT49
IOVA

Iovance Biotherapeutics

Caricamento quotazioni...

Previsioni

Il prezzo obiettivo medio degli analisti è 12,34 € (+80,15%). La mediana è 13,65 € (+99,27%).

Acquista
  15
Mantieni
  6
Vendi
  0

Discussioni nella community

Non ci sono ancora discussioni su questo asset.

Avvia discussione

  • Iovance Biotherapeutics raises annual guidance after strong demand for Amtagvi and Proleukin

    Strong market demand for the cancer therapies Amtagvi (Lifileucel) and Proleukin has led Iovance Biotherapeutics to significantly raise its annual forecast. The company is expanding its TIL therapy platform and broadening the clinical pipeline for additional solid tumors. Despite a weak overall market, investors are drawing the stock higher, signaling company-specific momentum. » Altro su finanzen.net


  • Iovance raises 2026 revenue forecast after strong demand for Amtagvi

    Iovance raised its 2026 revenue forecast to $410–420 million, supported by rising U.S. demand for Amtagvi and Proleukin. Shorter production times and more than 110 treatment centers are driving growth and pushed the stock up about 10% to a 52-week high. The business remains based on tumor-infiltrating lymphocytes (TIL), which are increasingly entering clinical practice for solid tumors. » Altro su finanzen.net


  • Iovance Biotherapeutics accelerates revenue growth after successful launch of Amtagvi

    Iovance Biotherapeutics is commercializing Amtagvi, the world’s first approved personalized TIL cell therapy for advanced melanoma. Rapid onboarding of specialized treatment centers and rising patient demand are driving dynamic revenue acceleration in the current fiscal year. Analysts view the first-mover advantage and the successful market entry as drivers for further operational growth. » Altro su finanzen.net


  • Iovance Biotherapeutics reaches 52-week high at $9.36

    Iovance Biotherapeutics shares rose to a 52-week high of $9.36, delivering a year-to-date return of 215% and nearly a 279% gain over the past year; market capitalization is around $4.2 billion. In Q2 2026 the company reported record revenue of $99.31 million, driven by strong sales of the cancer therapy Amtagvi ($91 million), and an adjusted loss of $0.11 per share, beating expectations. UBS raised its price target to $7.00 (rating: neutral), TD Cowen increased its target to $10.00 and maintained buy; InvestingPro currently considers the stock overvalued. » Altro su de.investing.com


  • Iovance reports record Q2 revenue and reviews 2026 guidance on strong Amtagvi demand

    Iovance reported record Q2 revenue of about $99.3 million, a 66% year-over-year increase driven by strong Amtagvi sales (U.S. Amtagvi ~$91M) and Proleukin ~$9M. Gross margin improved to 56% on higher volumes, manufacturing efficiencies and cost optimisation, while R&D expenses fell for a fourth consecutive quarter. Management is reviewing its 2026 revenue guidance of $350–370 million with an updated outlook expected in Q3, and continues expanding its treatment network to over 95 centres (forecasting at least 110 by year-end). The company finished the quarter with roughly $304 million in cash and is advancing multiple late‑stage clinical programmes and international regulatory submissions. » Altro su finance.yahoo.com

Nel 2022, Iovance Biotherapeutics ha già distribuito 0,26 € di dividendi. L'ultimo pagamento è avvenuto a marzo 2022.

Dati finanziari dell'azienda

Nell'ultimo trimestre, Iovance Biotherapeutics ha registrato ricavi pari a 107,24 Mln € e un utile netto di -19,66 Mln €
(EUR) settembre 2026
YoY
Ricavi 107,24 Mln 86,57%
Utile lordo 64,84 Mln 162,57%
Utile netto -19,66 Mln 74,71%
EBITDA -10,74 Mln 83,90%

Dati fondamentali

Metrica Valore
Capitalizzazione di mercato
3,14 Mld €
Numero di azioni
462,66 Mln
Massimo/minimo a 52 settimane
13,98 € - 1,89 €
Dividendi No
Beta
0,76
Rapporto P/E
-14,08
Rapporto PEG
-0,15
Rapporto P/B
4,19
Rapporto P/S
9,11

Profilo aziendale

Iovance Biotherapeutics, Inc., una società biotecnologica in fase di sviluppo clinico, si occupa dello sviluppo e della commercializzazione di prodotti di immunoterapia oncologica per sfruttare la potenza del sistema immunitario del paziente al fine di eradicare le cellule tumorali. Sono in corso sei studi clinici di fase 2, tra cui C-144-01, relativo al suo principale candidato prodotto, lifileucel, per il trattamento del melanoma metastatico; C-145-04, relativo al candidato prodotto lifileucel per il carcinoma cervicale ricorrente, metastatico o persistente; e C-145-03, relativo al candidato prodotto LN-145, per il carcinoma a cellule squamose della testa e del collo ricorrente e/o metastatico. Iovance Biotherapeutics, Inc. ha collaborazioni e accordi di licenza con H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; e Novartis Pharma AG. La società era precedentemente nota come Lion Biotechnologies, Inc. e ha cambiato denominazione in Iovance Biotherapeutics, Inc. nel giugno 2017. Iovance Biotherapeutics, Inc. è stata costituita nel 2007 ed ha sede a San Carlos, California.

Nome
Iovance Biotherapeutics
CEO
Frederick G. Vogt
Sede centrale San Carlos, ca
Stati Uniti
Sito web
Settore
Sanità
Industria
Biotecnologia
Quotazione in borsa
15/10/2010
Dipendenti 975

Simboli di borsa

Borsa Simbolo
NASDAQ
IOVA
London Stock Exchange
0JDK.L
Frankfurt
2LB.F
Düsseldorf
2LB.DU
London
0JDK.L
München
2LB.MU
🍪

Parqet  usa i cookie. Scopri di più